Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation

Therapeutic Drug Monitoring

Volumn 30, Issue 6, 2008, Pages 656-661

  Mino, Yasuaki ^a,b   Naito, Takafumi ^a   Matsushita, Tomomi ^a,b   Otsuka, Atsushi ^a   Ushiyama, Tomomi ^a   Ozono, Seiichiro ^a   Hishida, Akira ^a   Kagawa, Yoshiyuki ^b   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Kidney transplantation; Lupus nephritis; Mycophenolic acid; Mycophenolic acid glucuronide; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCURONIDE; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID PHENOLIC GLUCURONIDE; PREDNINE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 57749086299     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31818b8244     Document Type: Article

References (34)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-424.
2. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus. 2007;16:212-216.
3. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083.
4. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980.
5. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228.
6. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil. Transplant Proc. 1996;28:925-929.
7. Magee CC, Pascual M. Update in renal transplantation. Arch Intern Med. 2004;164:1373-1388.
8. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
9. Pillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporine concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001;34:77-81.
10. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248.
11. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004;75:434-447.
12. Naesens M, de Loor H, Vanrenterghem Y, et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation. 2007;84:362-373.
13. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant patients. Clin Pharmacol Ther. 1999;66:492-500.
14. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
15. Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005;60:249-256.
16. Filler G, Hansen M, LeBlanc C, et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol. 2003;18:445-449.
17. Neumann I, Haidinger M, Jager H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant patients. J Am Soc Nephrol. 2003;14:721-727.
18. Neumann I, Fuhrmann H, Kanzler M, et al. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with auto-immune disease and renal allograft. Expert Opin Pharmacother. 2008;9:879-886.
19. Mino Y, Naito T, Matsushita T, et al. Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. J Pharm Biomed Anal. 2008;46:603-608.
20. Czock D, Rasche FM, Carius A, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. J Clin Pharmacol. 2007;47:850-859.
21. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
22. Kuriata-Kordek M, Boratynska M, Falkiewicz K, et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc. 2003;35:2369-2371.
23. Naito T, Shinno K, Maeda T, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006;29:275-280.
24. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
25. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
26. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
27. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporine A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
28. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
29. Morissette P, Albert C, Busque S, et al. In vivo higher glucuronidation of mycophenolic acid in male than in female patients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit. 2001;23:520-525.
30. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft patients. Am J Transplant. 2003;3:1581-1586.
31. Bernard O, Tojcic J, Journault K, et al. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos. 2006;34:1539-1545.
32. Levesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81:392-400.
33. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007;63:1161-1169.
34. Le Guellec C, Büchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57:805-811.